KRYS Krystal Biotech, Inc.
Q3 2025 10-Q
Filed: Nov 3, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Krystal Biotech, Inc. (KRYS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New regulatory risk: FDA label update for VYJUVEK in Sep 2025 expands treatment to birth and allows patient/caregiver administration at home, increasing compliance complexity
- • Material update in clinical risk: Phase 3 IOLITE study for KB803 ocular treatment ongoing with decentralized home dosing; enrollment expected complete by year end
Quarterly Financial SummaryXBRL
Revenue
$98M
Net Income
$79M
Operating Margin
42.5%
Net Margin
81.1%
ROE
7.0%
Total Assets
$1.2B
Source: XBRL data from Krystal Biotech, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Krystal Biotech, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.